<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Morphology</journal-id><journal-title-group><journal-title xml:lang="en">Morphology</journal-title><trans-title-group xml:lang="ru"><trans-title>Морфология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1026-3543</issn><issn publication-format="electronic">2949-2556</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">628871</article-id><article-id pub-id-type="doi">10.17816/morph.628871</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Научные обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Tumor-infiltrating lymphocytes: opportunities to use their potential in clinical practice in breast cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Опухоль-инфильтрирующие лимфоциты: возможность использования их потенциала в клинической практике при раке молочной железы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7147-7912</contrib-id><contrib-id contrib-id-type="spin">6975-6677</contrib-id><name-alternatives><name xml:lang="en"><surname>Mnikhovich</surname><given-names>Maxim V.</given-names></name><name xml:lang="ru"><surname>Мнихович</surname><given-names>Максим Валерьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>mnichmaxim@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2949-1432</contrib-id><name-alternatives><name xml:lang="en"><surname>Erofeeva</surname><given-names>Lyudmila M.</given-names></name><name xml:lang="ru"><surname>Ерофеева</surname><given-names>Людмила Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Biology), Professor</p></bio><bio xml:lang="ru"><p>д-р биол. наук, профессор</p></bio><email>gystology@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-3625-692X</contrib-id><contrib-id contrib-id-type="spin">6039-7943</contrib-id><name-alternatives><name xml:lang="en"><surname>Borisov</surname><given-names>Denis A.</given-names></name><name xml:lang="ru"><surname>Борисов</surname><given-names>Денис Алексеевич</given-names></name></name-alternatives><email>borisofdenis@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-2468-2200</contrib-id><contrib-id contrib-id-type="spin">7991-6697</contrib-id><name-alternatives><name xml:lang="en"><surname>Timofeev</surname><given-names>Roman G.</given-names></name><name xml:lang="ru"><surname>Тимофеев</surname><given-names>Роман Геннадьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>Timofrg@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-4877-9569</contrib-id><contrib-id contrib-id-type="spin">2726-5343</contrib-id><name-alternatives><name xml:lang="en"><surname>Agafonova</surname><given-names>Yulia S.</given-names></name><name xml:lang="ru"><surname>Агафонова</surname><given-names>Юлия Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>yuliaagaf2000@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7792-1594</contrib-id><contrib-id contrib-id-type="spin">3943-4400</contrib-id><name-alternatives><name xml:lang="en"><surname>Bezuglova</surname><given-names>Tatyana V.</given-names></name><name xml:lang="ru"><surname>Безуглова</surname><given-names>Татьяна Васильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Biology)</p></bio><bio xml:lang="ru"><p>канд. биол. наук</p></bio><email>bezuglovat@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5947-1523</contrib-id><contrib-id contrib-id-type="spin">3691-0148</contrib-id><name-alternatives><name xml:lang="en"><surname>Shiripenko</surname><given-names>Ivan A.</given-names></name><name xml:lang="ru"><surname>Ширипенко</surname><given-names>Иван Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>hikkiwahikki@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Avtsyn Research Institute of Human Morphology of Petrovsky National Research Centre of Surgery</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт морфологии человека имени академика А.П. Авцына Российского научного центра хирургии имени академика Б.В. Петровского</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N.I. Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">Российский национальный исследовательский медицинский университет имени Н.И. Пирогова</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-04-12" publication-format="electronic"><day>12</day><month>04</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2023</year></pub-date><volume>161</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>97</fpage><lpage>105</lpage><history><date date-type="received" iso-8601-date="2024-03-07"><day>07</day><month>03</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-04-02"><day>02</day><month>04</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Эко-Вектор</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2026-07-15"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://j-morphology.com/1026-3543/article/view/628871">https://j-morphology.com/1026-3543/article/view/628871</self-uri><abstract xml:lang="en"><p>Tumor-infiltrating lymphocytes are currently considered as a prognostic biomarker of cancer patient survival and response to therapy, as well as a target for immunotherapy. However, tumor-infiltrating lymphocytes are only part of the tumor microenvironment, which consists of cellular and cytokine components. The cellular component also includes tumor-associated macrophages, neutrophils, fibroblasts and other cells. The cytokine component is represented by the products of the activity of all cells of the microenvironment, as well as tumor cells.</p> <p>This review examines various subpopulations of tumor-infiltrating lymphocytes, shows their interaction with tumor cells and other cell populations of the tumor microenvironment, and also describes the potential for clinical use of this cell population as a biomarker for predicting clinical outcomes and the possibility of their use to determine the most effective treatment for breast cancer.</p> <p>Obtaining new data on the previously poorly studied components of the tumor microenvironment and tumor-infiltrating lymphocytes, as well as the formation of ideas about the mutual influence of tumor microenvironment cells and tumor cells open up the prospect of developing innovative models of therapy. One of the modern directions is the search for molecular mechanisms of maintaining the antitumor activity of tumor-infiltrating lymphocytes, as well as the polarization of cells in the tumor microenvironment. Advances in the field of molecular oncology will make it possible to reduce the mortality rate of cancer patients to minimal levels while maintaining or even improving their standard of living.</p></abstract><trans-abstract xml:lang="ru"><p>Опухоль-инфильтрирующие лимфоциты в настоящее время рассматривают как прогностический биомаркёр выживаемости онкологических больных и эффективности ответа на проводимую терапию, а также как мишень для иммунотерапии. Однако такие лимфоциты являются только частью опухолевого микроокружения, состоящего из клеточного и цитокинового компонентов. К клеточному компоненту относят также ассоциированные с опухолью макрофаги, нейтрофилы, фибробласты и другие клетки. Цитокиновое составляющее представлено продуктами деятельности всех клеток микроокружения, а также опухолевыx клеток.</p> <p>В настоящем обзоре рассмотрены различные субпопуляции опухоль-инфильтрирующих лимфоцитов, показано их взаимодействие с опухолевыми клетками и другими клеточными популяциями опухолевого микроокружения, а также описаны возможности клинического применения этой клеточной популяции как биомаркёра прогноза клинических исходов и для определения наиболее эффективного метода лечения при раке молочной железы.</p> <p>Получение новых данных о ранее мало исследованных составляющих опухолевого микроокружения и опухоль-инфильтрирующих лимфоцитах, а также формирование представлений о взаимном влиянии клеток опухолевого микроокружения и опухолевых клеток открывает перспективу разработки инновационных моделей терапии. Одним из современных направлений является поиск молекулярных механизмов поддержания противоопухолевой активности опухоль-инфильтрирующих лимфоцитов, а также поляризации клеток опухолевого микроокружения. Успехи в области молекулярной онкологии позволят снизить смертность онкобольных до минимальных значений с сохранением или даже улучшением их уровня жизни.</p></trans-abstract><kwd-group xml:lang="en"><kwd>tumor microenvironment studies</kwd><kwd>tumor-infiltrating lymphocytes</kwd><kwd>breast cancer</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>опухолевое микроокружение</kwd><kwd>опухоль-инфильтрирующие лимфоциты</kwd><kwd>рак молочной железы</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Annaratone L, Cascardi E, Vissio E, et al. The multifaceted nature of tumor microenvironment in breast carcinomas. Pathobiology. 2020;87(2):125–142. doi: 10.1159/000507055</mixed-citation><mixed-citation xml:lang="ru">Annaratone L., Cascardi E., Vissio E., et al. The multifaceted nature of tumor microenvironment in breast carcinomas // Pathobiology. 2020. Vol. 87, N 2. С. 125–142. doi: 10.1159/000507055</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Tsang JYS, Tse GM. Molecular classification of breast cancer. Adv Anat Pathol. 2020; 27(1):27–35. doi: 10.1097/PAP.0000000000000232</mixed-citation><mixed-citation xml:lang="ru">Tsang J.Y.S., Tse G.M. Molecular classification of breast cancer // Adv Anat Pathol. 2020. Vol. 27, N 1. P. 27–35. doi: 10.1097/PAP.0000000000000232</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Mei P, Freitag CE, Wei L, et al. High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas. Diagn Pathol. 2020;15(1):50. doi: 10.1186/s13000-020-00971-7</mixed-citation><mixed-citation xml:lang="ru">Mei P., Freitag C.E., Wei L., et al. High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas // Diagn Pathol. 2020. Vol. 15, N 1. P. 50. doi: 10.1186/s13000-020-00971-7</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Segovia-Mendoza M, Morales-Montor J. Immune tumor microenvironment in breast cancer and the participation of estrogen and its receptors in cancer physiopathology. Front Immunol. 2019;10:348. doi: 10.3389/fimmu.2019.00348</mixed-citation><mixed-citation xml:lang="ru">Segovia-Mendoza M., Morales-Montor J. Immune tumor microenvironment in breast cancer and the participation of estrogen and its receptors in cancer physiopathology // Front Immunol. 2019. Vol. 10. P. 348. doi: 10.3389/fimmu.2019.00348</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Ogiya R, Niikura N, Kumaki N, et al. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci. 2016;107(12):1730–1735. doi: 10.1111/cas.13101</mixed-citation><mixed-citation xml:lang="ru">Ogiya R., Niikura N., Kumaki N., et al. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients // Cancer Sci. 2016. Vol. 107, N 12. P. 1730–1735. doi: 10.1111/cas.13101</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Sobottka B, Pestalozzi B, Fink D, et al. Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. Oncoimmunology. 2016;5(6):e1153208. doi: 10.1080/2162402X.2016.1153208</mixed-citation><mixed-citation xml:lang="ru">Sobottka B., Pestalozzi B., Fink D., et al. Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases // Oncoimmunology. 2016. Vol. 5, N 6. P. e1153208. doi: 10.1080/2162402X.2016.1153208</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Egelston CA, Guo W, Tan J, et al. Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer. JCI Insight. 2022;7(3):e153963. doi: 10.1172/jci.insight.153963</mixed-citation><mixed-citation xml:lang="ru">Egelston C.A., Guo W., Tan J., et al. Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer // JCI Insight. 2022. Vol. 7, N 3. P. e153963. doi: 10.1172/jci.insight.153963</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Oshi M, Asaoka M, Tokumaru Y, et al. CD8 T cell score as a prognostic biomarker for triple negative breast cancer. Int J Mol Sci. 2020;21(18):6968. doi: 10.3390/ijms21186968</mixed-citation><mixed-citation xml:lang="ru">Oshi M., Asaoka M., Tokumaru Y., et al. CD8 T cell score as a prognostic biomarker for triple negative breast cancer // Int J Mol Sci. 2020. Vol. 21, N 18. P. 6968. doi: 10.3390/ijms21186968</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Sobral-Leite M, Salomon I, Opdam M, et al. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Res. 2019;21(1):90. doi: 10.1186/s13058-019-1176-2</mixed-citation><mixed-citation xml:lang="ru">Sobral-Leite M., Salomon I., Opdam M., et al. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes // Breast Cancer Res. 2019. Vol. 21, N 1. P. 90. doi: 10.1186/s13058-019-1176-2</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Glajcar A, Szpor J, Hodorowicz-Zaniewska D, et al. The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status. Virchows Arch. 2019;475(1):13–23. doi: 10.1007/s00428-019-02568-y</mixed-citation><mixed-citation xml:lang="ru">Glajcar A., Szpor J., Hodorowicz-Zaniewska D., et al. The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status // Virchows Arch. 2019. Vol. 475, N 1. P. 13–23. doi: 10.1007/s00428-019-02568-y</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Wang S, Yao Y, Yao M, et al. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways. Biochem Biophys Res Commun. 2018;503(3):1605–1609. doi: 10.1016/j.bbrc.2018.07.088</mixed-citation><mixed-citation xml:lang="ru">Wang S., Yao Y., Yao M., et al. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways // Biochem Biophys Res Commun. 2018. Vol. 503, N 3. P. 1605–1609. doi: 10.1016/j.bbrc.2018.07.088</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Karpisheh V, Ahmadi M, Abbaszadeh-Goudarzi K, et al. The role of Th17 cells in the pathogenesis and treatment of breast cancer. Cancer Cell Int. 2022;22(1):108. doi: 10.1186/s12935-022-02528-8</mixed-citation><mixed-citation xml:lang="ru">Karpisheh V., Ahmadi M., Abbaszadeh-Goudarzi K., et al. The role of Th17 cells in the pathogenesis and treatment of breast cancer // Cancer Cell Int. 2022. Vol. 22, N 1. P. 108. doi: 10.1186/s12935-022-02528-8</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Kos K, de Visser KE. The multifaceted role of regulatory t cells in breast cancer. Annu Rev Cancer Biol. 2021;5:291–310. doi: 10.1146/annurev-cancerbio-042920-104912</mixed-citation><mixed-citation xml:lang="ru">Kos K., de Visser K.E. The multifaceted role of regulatory t cells in breast cancer // Annu Rev Cancer Biol. 2021. Vol. 5. P. 291–310. doi: 10.1146/annurev-cancerbio-042920-104912</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Peng GL, Li L, Guo YW, et al. CD8+ cytotoxic and FoxP3+ regulatory T lymphocytes serve as prognostic factors in breast cancer. Am J Transl Res. 2019;11(8):5039–5053.</mixed-citation><mixed-citation xml:lang="ru">Peng G.L., Li L., Guo Y.W., et al. CD8+ cytotoxic and FoxP3+ regulatory T lymphocytes serve as prognostic factors in breast cancer // Am J Transl Res. 2019. Vol. 11, N 8. P. 5039–5053.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Solis-Castillo LA, Garcia-Romo GS, Diaz-Rodriguez A, et al. Tumor-infiltrating regulatory T cells, CD8/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer. Breast Cancer. 2020;27(5):837–849. doi: 10.1007/s12282-020-01079-y</mixed-citation><mixed-citation xml:lang="ru">Solis-Castillo L.A., Garcia-Romo G.S., Diaz-Rodriguez A., et al. Tumor-infiltrating regulatory T cells, CD8/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer // Breast Cancer. 2020. Vol. 27, N 5. P. 837–849. doi: 10.1007/s12282-020-01079-y</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Laumont CM, Banville AC, Gilardi M, et al. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat Rev Cancer. 2022;22(7):414–430. doi: 10.1038/s41568-022-00466-1</mixed-citation><mixed-citation xml:lang="ru">Laumont C.M., Banville A.C., Gilardi M., et al. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities // Nat Rev Cancer. 2022. Vol. 22, N 7. P. 414–430. doi: 10.1038/s41568-022-00466-1</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Hu Q, Hong Y, Qi P, et al. Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. Nat Commun. 2021;12(1):2186. doi: 10.1038/s41467-021-22300-2</mixed-citation><mixed-citation xml:lang="ru">Hu Q., Hong Y., Qi P., et al. Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling // Nat Commun. 2021. Vol. 12, N 1. P. 2186. doi: 10.1038/s41467-021-22300-2</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Noël G, Fontsa ML, Garaud S, et al. Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. Clin Invest. 2021;131(19):e139905. doi: 10.1172/JCI139905</mixed-citation><mixed-citation xml:lang="ru">Noël G., Fontsa M.L., Garaud S., et al. Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity // J Clin Invest. 2021. Vol. 131, N 19. P. e139905. doi: 10.1172/JCI139905</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Mehta AK, Kadel S, Townsend MG, et al. Macrophage biology and mechanisms of immune suppression in breast cancer. Front Immunol. 2021;12:643771. doi: 10.3389/fimmu.2021.643771</mixed-citation><mixed-citation xml:lang="ru">Mehta A.K., Kadel S., Townsend M.G., et al. Macrophage biology and mechanisms of immune suppression in breast cancer // Front Immunol. 2021. Vol. 12. P. 643771. doi: 10.3389/fimmu.2021.643771</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Castellaro AM, Rodriguez-Baili MC, Di Tada CE, Gil GA. Tumor-associated macrophages induce endocrine therapy resistance in ER+ breast cancer cells. Cancers (Basel). 2019;11(2):189. doi: 10.3390/cancers11020189</mixed-citation><mixed-citation xml:lang="ru">Castellaro A.M., Rodriguez-Baili M.C., Di Tada C.E., Gil G.A. Tumor-associated macrophages induce endocrine therapy resistance in ER+ breast cancer cells // Cancers (Basel). 2019. Vol. 11, N 2. P. 189. doi: 10.3390/cancers11020189</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Kuroda H, Jamiyan T, Yamaguchi R, et al. Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes. Clin Transl Oncol. 2021;23(12):2513–2525. doi: 10.1007/s12094-021-02652-3</mixed-citation><mixed-citation xml:lang="ru">Kuroda H., Jamiyan T., Yamaguchi R., et al. Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes // Clin Transl Oncol. 2021. Vol. 23, N 12. P. 2513–2525. doi: 10.1007/s12094-021-02652-3</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Minns D, Smith KJ, Hardisty G, et al. The outcome of neutrophil-t cell contact differs depending on activation status of both cell types. Front Immunol. 2021;12:633486. doi: 10.3389/fimmu.2021.633486</mixed-citation><mixed-citation xml:lang="ru">Minns D., Smith K.J., Hardisty G., et al. The outcome of neutrophil-t cell contact differs depending on activation status of both cell types // Front Immunol. 2021. Vol. 12. P. 633486. doi: 10.3389/fimmu.2021.633486</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Ohms M, Möller S, Laskay T. An attempt to polarize human neutrophils toward n1 and n2 phenotypes in vitro. Front Immunol. 2020;11:532. doi: 10.3389/fimmu.2020.00532</mixed-citation><mixed-citation xml:lang="ru">Ohms M., Möller S., Laskay T. An attempt to polarize human neutrophils toward N1 and N2 phenotypes in vitro // Front Immunol. 2020. Vol. 11. P. 532. doi: 10.3389/fimmu.2020.00532</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Geng SK, Fu SM, Ma SH, et al. Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy. BMC Cancer. 2021;21(1):68. doi: 10.1186/s12885-021-07789-6</mixed-citation><mixed-citation xml:lang="ru">Geng S.K., Fu S.M., Ma S.H., et al. Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy // BMC Cancer. 2021. Vol. 21, N 1. P. 68. doi: 10.1186/s12885-021-07789-6</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Hu G, Xu F, Zhong K, et al. Activated tumor-infiltrating fibroblasts predict worse prognosis in breast cancer patients. J Cancer. 2018;9(20):3736–3742. doi: 10.7150/jca.28054</mixed-citation><mixed-citation xml:lang="ru">Hu G., Xu F., Zhong K., et al. Activated tumor-infiltrating fibroblasts predict worse prognosis in breast cancer patients // J Cancer. 2018. Vol. 9, N 20. P. 3736–3742. doi: 10.7150/jca.28054</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33(3):463–479.e10. doi: 10.1016/j.ccell.2018.01.011</mixed-citation><mixed-citation xml:lang="ru">Costa A., Kieffer Y., Scholer-Dahirel A., et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer // Cancer Cell. 2018. Vol. 33, N 3. P. 463–479.e10. doi: 10.1016/j.ccell.2018.01.011</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Kuczek DE, Larsen AMH, Thorseth ML, et al. Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer. 2019;7(1):68. doi: 10.1186/s40425-019-0556-6</mixed-citation><mixed-citation xml:lang="ru">Kuczek D.E., Larsen A.M.H., Thorseth M.L., et al. Collagen density regulates the activity of tumor-infiltrating T cells // J Immunother Cancer. 2019. Vol. 7, N 1. P. 68. doi: 10.1186/s40425-019-0556-6</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Elaraby E, Malek AI, Abdullah HW, et al. Natural killer cell dysfunction in obese patients with breast cancer: a review of a triad and its implications. J Immunol Res. 2021;2021:9972927. doi: 10.1155/2021/9972927</mixed-citation><mixed-citation xml:lang="ru">Elaraby E., Malek A.I., Abdullah H.W., et al. Natural killer cell dysfunction in obese patients with breast cancer: a review of a triad and its implications // J Immunol Res. 2021. Vol. 2021. P. 9972927. doi: 10.1155/2021/9972927</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Bouzidi L, Triki H, Charfi S, et al. Prognostic value of natural killer cells besides tumor-infiltrating lymphocytes in breast cancer tissues. Clin Breast Cancer. 2021;21(6):e738–e747. doi: 10.1016/j.clbc.2021.02.003</mixed-citation><mixed-citation xml:lang="ru">Bouzidi L., Triki H., Charfi S., et al. Prognostic value of natural killer cells besides tumor-infiltrating lymphocytes in breast cancer tissues // Clin Breast Cancer. 2021. Vol. 21, N 6. P. e738–e747. doi: 10.1016/j.clbc.2021.02.003</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">O’Meara T, Marczyk M, Qing T, et al. Immunological differences between immune-rich estrogen receptor-positive and immune-rich triple-negative breast cancers. JCO Precis Oncol. 2020;4:PO.19.00350. doi: 10.1200/PO.19.00350</mixed-citation><mixed-citation xml:lang="ru">O’Meara T., Marczyk M., Qing T., et al. Immunological differences between immune-rich estrogen receptor-positive and immune-rich triple-negative breast cancers // JCO Precis Oncol. 2020. Vol. 4. P. PO.19.00350. doi: 10.1200/PO.19.00350.</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Chan IS, Knútsdóttir H, Ramakrishnan G, et al. Cancer cells educate natural killer cells to a metastasis-promoting cell state. J Cell Biol. 2020;219(9):e202001134. doi: 10.1083/jcb.202001134</mixed-citation><mixed-citation xml:lang="ru">Chan I.S., Knútsdóttir H., Ramakrishnan G., et al. Cancer cells educate natural killer cells to a metastasis-promoting cell state // J Cell Biol. 2020. Vol. 219, N 9. P. e202001134. doi: 10.1083/jcb.202001134</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Al Absi A, Wurzer H, Guerin C, et al. Actin cytoskeleton remodeling drives breast cancer cell escape from natural killer–mediated cytotoxicity. Cancer Res. 2018;78(19):5631–5643. doi: 10.1158/0008-5472.CAN-18-0441</mixed-citation><mixed-citation xml:lang="ru">Al Absi A., Wurzer H., Guerin C., et al. Actin cytoskeleton remodeling drives breast cancer cell escape from natural killer–mediated cytotoxicity // Cancer Res. 2018. Vol. 78, N 19. P. 5631–5643. doi: 10.1158/0008-5472.CAN-18-0441</mixed-citation></citation-alternatives></ref></ref-list></back></article>
